Works by Popat, Rakesh

Results: 85
    1
    2

    Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.

    Published in:
    2020
    By:
    • Koutoukidis, Dimitrios A.;
    • Land, Joanne;
    • Hackshaw, Allan;
    • Heinrich, Malgorzata;
    • McCourt, Orla;
    • Beeken, Rebecca J.;
    • Philpott, Stephanie;
    • DeSilva, Dunnya;
    • Rismani, Ali;
    • Rabin, Neil;
    • Popat, Rakesh;
    • Kyriakou, Charalampia;
    • Papanikolaou, Xenofon;
    • Mehta, Atul;
    • Paton, Bruce;
    • Fisher, Abigail;
    • Yong, Kwee L.
    Publication type:
    journal article
    3
    4
    5
    6

    High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00717-2
    By:
    • Khwaja, Jahanzaib;
    • Bomsztyk, Joshua;
    • Mahmood, Shameem;
    • Wisniowski, Brendan;
    • Shah, Raakhee;
    • Tailor, Anish;
    • Yong, Kwee;
    • Popat, Rakesh;
    • Rabin, Neil;
    • Kyriakou, Charalampia;
    • Sive, Jonathan;
    • Esposti, Simona Degli;
    • Larkin, Daniel F. P.;
    • Worthington, Sarah;
    • Hart, Alyse;
    • Dowling, Emma;
    • Correia, Nuno;
    • Bygrave, Ceri;
    • Rydzewski, Andrzej;
    • Jamroziak, Krzysztof
    Publication type:
    Article
    7
    8

    Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00494-4
    By:
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Potter, Heather A.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Degli Esposti, Simona;
    • Byrne, Julie;
    • Opalinska, Joanna;
    • Baron, January;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Dana, Reza;
    • Farooq, Asim V.;
    • Colby, Kathryn;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    9

    Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.

    Published in:
    2020
    By:
    • Farooq, Asim V.;
    • Degli Esposti, Simona;
    • Popat, Rakesh;
    • Thulasi, Praneetha;
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Jakubowiak, Andrzej;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Opalinska, Joanna;
    • Baron, January;
    • Piontek, Trisha;
    • Byrne, Julie;
    • Gupta, Ira;
    • Colby, Kathryn
    Publication type:
    Correction Notice
    10

    Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.

    Published in:
    Ophthalmology & Therapy, 2020, v. 9, n. 4, p. 889, doi. 10.1007/s40123-020-00280-8
    By:
    • Farooq, Asim V.;
    • Degli Esposti, Simona;
    • Popat, Rakesh;
    • Thulasi, Praneetha;
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Jakubowiak, Andrzej;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Opalinska, Joanna;
    • Baron, January;
    • Piontek, Trisha;
    • Byrne, Julie;
    • Gupta, Ira;
    • Colby, Kathryn
    Publication type:
    Article
    11

    Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 8, p. 1465, doi. 10.1080/10428194.2023.2216817
    By:
    • Nesr, George;
    • Shah, Raakhee;
    • Kyriakou, Charalampia;
    • Sive, Jonathan;
    • Popat, Rakesh;
    • Yong, Kwee;
    • Wisniowski, Brendan;
    • Xu, Ke;
    • Wechalekar, Ashu;
    • Lee, Lydia;
    • Ings, Stuart;
    • Papanikolaou, Xenofon;
    • Mahmood, Shameem;
    • Mcmillan, Annabel;
    • Horder, Jackie;
    • Newrick, Fiona;
    • Marfil, Jotham;
    • Ainley, Louise;
    • Asher, Samir;
    • Cheesman, Simon
    Publication type:
    Article
    12

    Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 10, p. 2489, doi. 10.1080/10428194.2022.2074989
    By:
    • Howells, Lara;
    • Chan, Wei Yee;
    • Sanchez, Emilie;
    • Horder, Jacqueline;
    • Newrick, Fiona;
    • Marfil, Jotham;
    • McMillan, Annabel;
    • Wisniowski, Brendan;
    • Mahmood, Shameem;
    • Papanikolaou, Xenofon;
    • Lee, Lydia;
    • Wechalekar, Ashutosh;
    • Popat, Rakesh;
    • Sive, Jonathan;
    • Kyriakou, Charalampia;
    • Xu, Ke;
    • Nastouli, Eleni;
    • Yong, Kwee L.;
    • Rabin, Neil
    Publication type:
    Article
    13
    14
    15
    16

    The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study.

    Published in:
    Supportive Care in Cancer, 2024, v. 32, n. 7, p. 1, doi. 10.1007/s00520-024-08663-4
    By:
    • Buck, Caroline;
    • Brenes Castillo, Francisco;
    • Bettio, Elena;
    • Land, Joanne;
    • McCourt, Orla;
    • Poole, Helen;
    • Tarling, Rachel;
    • Yong, Kwee;
    • Popat, Rakesh;
    • Lee, Lydia;
    • McMillan, Annabel;
    • Papanikolaou, Xenofon;
    • Xu, Ke;
    • Kyriakou, Chara;
    • Rabin, Neil;
    • Wechalekar, Ashu;
    • Fisher, Abigail;
    • Sive, Jonathan
    Publication type:
    Article
    17

    The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study.

    Published in:
    Supportive Care in Cancer, 2022, v. 30, n. 9, p. 7469, doi. 10.1007/s00520-022-07173-5
    By:
    • Camilleri, Marquita;
    • Bekris, Georgios;
    • Sidhu, Govundeep;
    • Buck, Caroline;
    • Elsden, Esma;
    • McCourt, Orla;
    • Horder, Jackie;
    • Newrick, Fiona;
    • Lecat, Catherine;
    • Sive, Jonathan;
    • Papanikolaou, Xenofon;
    • Popat, Rakesh;
    • Lee, Lydia;
    • Xu, Ke;
    • Kyriakou, Charalampia;
    • Rabin, Neil;
    • Yong, Kwee;
    • Fisher, Abigail
    Publication type:
    Article
    18
    19
    20

    Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. 665, doi. 10.1016/j.clml.2024.05.003
    By:
    • Chari, Ajai;
    • Krishnan, Amrita;
    • Rasche, Leo;
    • Ye, Jing Christine;
    • Garfall, Alfred;
    • Popat, Rakesh;
    • Lipe, Brea;
    • Qin, Xiang;
    • Campagna, Michela;
    • Masterson, Tara;
    • Tomlinson, Chalmer;
    • Hilder, Brandi;
    • Tolbert, Jaszianne;
    • Renaud, Thomas;
    • Smit, M. Damiette;
    • Gray, Kathleen;
    • Kane, Colleen;
    • Heuck, Christoph;
    • Donk, Niels W.C.J. van de
    Publication type:
    Article
    21

    Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 3, p. 194, doi. 10.1016/j.clml.2023.11.001
    By:
    • Martin, Thomas G.;
    • Moreau, Philippe;
    • Usmani, Saad Z.;
    • Garfall, Alfred;
    • Mateos, Maria-Victoria;
    • San-Miguel, Jesus F.;
    • Oriol, Albert;
    • Nooka, Ajay K.;
    • Rosinol, Laura;
    • Chari, Ajai;
    • Karlin, Lionel;
    • Krishnan, Amrita;
    • Bahlis, Nizar;
    • Popat, Rakesh;
    • Besemer, Britta;
    • Martfnez-Lopez, Joaquin;
    • Delforge, Michel;
    • Trancucci, Danielle;
    • Pei, Lixia;
    • Kobos, Rachel
    Publication type:
    Article
    22

    P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S160, doi. 10.1016/S2152-2650(21)02346-6
    By:
    • Terpos, Evangelos;
    • Badros, Ashraf Z.;
    • Popat, Rakesh;
    • Rodríguez-Otero, Paula;
    • Farooq, Asim V.;
    • Jeng, Bennie;
    • Esposti, Simona Degli;
    • Lewis, Eric;
    • Gupta, Ira;
    • Opalinska, Joanna;
    • Palumbo, Antonio;
    • Trudel, Suzanne;
    • Jadhav, Vinay
    Publication type:
    Article
    23

    P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
    By:
    • Lonial, Sagar;
    • Nooka, Ajay;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Prani Paka;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    24
    25

    OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S30, doi. 10.1016/S2152-2650(21)02121-2
    By:
    • Wei Yee Chan;
    • Howells, Lara;
    • Wilson, William;
    • Sanchez, Emilie;
    • Ainley, Louise;
    • Chavda, Selina;
    • Dowling, Emma;
    • Correia, Nuno;
    • Lecat, Catherine;
    • McMillan, Annabel;
    • Wisniowski, Brendan;
    • Mahmood, Shameem;
    • Papanikolaou, Xenofon;
    • Lee, Lydia;
    • Sive, Jonathan;
    • Kyriakou, Charalampia;
    • Wechalekar, Ashutosh;
    • Popat, Rakesh;
    • Rabin, Neil;
    • Nastouli, Eleni
    Publication type:
    Article
    26

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    27

    OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S2, doi. 10.1016/S2152-2650(21)02077-2
    By:
    • Popat, Rakesh;
    • Wilson, William;
    • Camilleri, Marquita;
    • Tute, Ruth De;
    • Pang, Gavin;
    • Jenner, Richard;
    • Dadaga, Tushhar;
    • Kamora, Sumaiya;
    • Streetly, Matthew;
    • Ramasamy, Karthik;
    • Phillips, Elizabeth;
    • Chapman, Mike;
    • Bygrave, Ceri;
    • Cavenagh, James;
    • Sive, Jonathan;
    • Benjamin, Reuben;
    • Eccersley, Lydia;
    • Hassan, Sandra;
    • Willis, Fenella;
    • Clifton-Hadley, Laura
    Publication type:
    Article
    28

    MM-200: A Qualitative Study of Patients' Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S428, doi. 10.1016/S2152-2650(21)01955-8
    By:
    • Thomas, Caitlin;
    • Gelhorn, Heather;
    • Mulnick, Sarah;
    • Popat, Rakesh;
    • Ailawadhi, Sikander;
    • Kleinman, David;
    • McDermott, Eleanor;
    • Gorsh, Boris;
    • Perera, Sue;
    • Eliason, Laurie;
    • Sapra, Sandhya;
    • Sansbury, Leah;
    • O'Neill, Alicia;
    • Paka, Prani;
    • Galinsky, Jayne;
    • Tolley, Julia;
    • Ross, Melissa
    Publication type:
    Article
    29

    MM-103: Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S421, doi. 10.1016/S2152-2650(21)01944-3
    By:
    • Terpos, Evangelos;
    • Badros, Ashraf;
    • Popat, Rakesh;
    • Rodriguez-Otero, Paula;
    • Farooq, Asim;
    • Jeng, Bennie;
    • Esposti, Simona Degli;
    • Lewis, Eric;
    • Gupta, Ira;
    • Opalinska, Joanna;
    • Palumbo, Antonio;
    • Trudel, Suzanne
    Publication type:
    Article
    30

    MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
    By:
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Paka, Prani;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    31

    Poster: MM-200: A Qualitative Study of Patients' Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S255, doi. 10.1016/S2152-2650(21)01598-6
    By:
    • Thomas, Caitlin;
    • Gelhorn, Heather;
    • Mulnick, Sarah;
    • Popat, Rakesh;
    • Ailawadhi, Sikander;
    • Kleinman, David;
    • McDermott, Eleanor;
    • Gorsh, Boris;
    • Perera, Sue;
    • Eliason, Laurie;
    • Sapra, Sandhya;
    • Sansbury, Leah;
    • O'Neill, Alicia;
    • Paka, Prani;
    • Galinsky, Jayne;
    • Tolley, Julia;
    • Ross, Melissa
    Publication type:
    Article
    32

    Poster: MM-103: Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01577-9
    By:
    • Terpos, Evangelos;
    • Badros, Ashraf;
    • Popat, Rakesh;
    • Rodriguez-Otero, Paula;
    • Farooq, Asim;
    • Jeng, Bennie;
    • Esposti, Simona Degli;
    • Lewis, Eric;
    • Gupta, Ira;
    • Opalinska, Joanna;
    • Palumbo, Antonio;
    • Trudel, Suzanne
    Publication type:
    Article
    33

    Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
    By:
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Paka, Prani;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    34

    Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e309, doi. 10.1016/j.clml.2019.09.508
    By:
    • Cohen, Oliver Charles;
    • Sharpley, Faye;
    • Gillmore, Julian;
    • Lachmann, Helen;
    • Sachchithanantham, Sajitha;
    • Mahmood, Shameem;
    • Quarta, Cristina;
    • Fontana, Marianna;
    • Whelan, Carol;
    • Martinez-Naharro, Ana;
    • Kyriakou, Charalampia;
    • Rabin, Neil;
    • Popat, Rakesh;
    • Yong, Kwee;
    • Cheesman, Simon;
    • Shah, Raakhee;
    • Hawkins, Philip;
    • Wechalekar, Ashutosh
    Publication type:
    Article
    35

    Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving ≥VGPR following PAD induction in the Phase 2 PADIMAC study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e288, doi. 10.1016/j.clml.2019.09.475
    By:
    • Chan, Wei Yee;
    • Counsell, Nicholas;
    • Popat, Rakesh;
    • De Tute, Ruth;
    • De-silva, Dunnya;
    • Phillips, Elizabeth;
    • Cavenagh, Jamie;
    • Adedayo, Toyin;
    • Braganca, Nivette;
    • Roddie, Claire;
    • Streetly, Matthew;
    • Schey, Steve;
    • Koh, Mickey;
    • Crowe, Josephine;
    • Quinn, Michael;
    • Morris, Curly;
    • D'Sa, Shirley;
    • Virchis, Andres;
    • Cook, Gordon;
    • Crawley, Charles
    Publication type:
    Article
    36
    37

    Comparison of PET Reconstruction Algorithms on Assessment and Quantification of FDG-PETCT Findings in Patients with Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e171, doi. 10.1016/j.clml.2019.09.286
    By:
    • Arulogun, Suzanne;
    • Riaz, Saima;
    • Rabin, Neil;
    • Smith, April-Louise;
    • Wan, Simon;
    • Yong, Kwee;
    • Kyriakou, Charalampia;
    • Wechalekar, Ashutosh;
    • Popat, Rakesh;
    • Sive, Jonathan;
    • Papanikolaou, Xenofon;
    • Mahmood, Shameem;
    • Sachchithanantham, Sajitha;
    • Bomanji, Jamshed
    Publication type:
    Article
    38
    39
    40

    A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e31, doi. 10.1016/j.clml.2019.09.046
    By:
    • Kumar, Shaji;
    • Harrison, Simon J.;
    • Cavo, Michele;
    • Rubia, Javier DE.LA.;
    • Popat, Rakesh;
    • Gasparetto, Cristina J.;
    • Hungria, Vania;
    • Salwender, Hans J.;
    • Suzuki, Kenshi;
    • Kim, Inho;
    • Punnoose, Elizabeth;
    • Hong, Wan-Jen;
    • Freise, Kevin J.;
    • Sood, Anjla;
    • Jalaluddin, Muhammad;
    • Ross, Jeremy;
    • Ward, James E.;
    • Maciag, Paulo;
    • Moreau, Philippe
    Publication type:
    Article
    41
    42
    43
    44

    A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 2, p. 328, doi. 10.1111/bjh.18216
    By:
    • Ravichandran, Sriram;
    • Mahmood, Shameem;
    • Wisniowski, Brenden;
    • Sachchithanantham, Sajitha;
    • Popat, Rakesh;
    • Lachmann, Helen;
    • Rabin, Neil;
    • Ramasamy, Karthik;
    • Hawkins, Stephen;
    • Kyriakou, Charalampia;
    • Gillmore, Julian;
    • Yong, Kwee;
    • Hawkins, Philip;
    • Jackson, Graham;
    • Pratt, Guy;
    • D. Wechalekar, Ashutosh
    Publication type:
    Article
    45
    46
    47
    48
    49

    Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

    Published in:
    British Journal of Haematology, 2022, v. 196, n. 4, p. e33, doi. 10.1111/bjh.17903
    By:
    • Chan, Wei Yee;
    • Counsell, Nicholas;
    • de Tute, Ruth;
    • De‐Silva, Dunnya;
    • Phillips, Elizabeth H.;
    • Cavenagh, Jamie;
    • Adedayo, Toyin;
    • Braganca, Nivette;
    • Roddie, Claire;
    • Streetly, Matthew;
    • Schey, Stephen;
    • Koh, Mickey B.C.;
    • Crowe, Josephine;
    • Morris, Treen C.;
    • Cook, Gordon;
    • Clifton‐Hadley, Laura;
    • Rabin, Neil;
    • Owen, Roger G.;
    • Popat, Rakesh;
    • Yong, Kwee L.
    Publication type:
    Article
    50

    Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.

    Published in:
    British Journal of Haematology, 2022, v. 196, n. 3, p. e21, doi. 10.1111/bjh.17864
    By:
    • Chan, Wei Yee;
    • Howells, Lara;
    • Wilson, William;
    • Sanchez, Emilie;
    • Ainley, Louise;
    • Chavda, Selina J.;
    • Dowling, Emma;
    • Correia, Nuno;
    • Lecat, Catherine S. Y.;
    • McMillan, Annabel;
    • Wisniowski, Brendan;
    • Mahmood, Shameem;
    • Papanikolaou, Xenofon;
    • Lee, Lydia;
    • Sive, Jonathan;
    • Kyriakou, Charalampia;
    • Wechalekar, Ashutosh;
    • Popat, Rakesh;
    • Rabin, Neil;
    • Nastouli, Eleni
    Publication type:
    Article